• 1
    Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1980; 352: 930942.
  • 2
    Ries LA, Eisner MP, Kosary CL, et al., editors. SEER cancer statistics review, 1975–2001. Bethesda: National Cancer Institute, 2004.
  • 3
    Winchester DP, Chang HR, Osteen RT, Menck HR. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer. 1996; 78: 18381843.
  • 4
    Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998; 339: 974984.
  • 5
    Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996; 14: 17181729.
  • 6
    van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 1996; 16: 714718.
  • 7
    Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001; 19: 33063311.
  • 8
    Meakin JW, Allt WE, Beale FA, et al. Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Res Treat. 1987; 3( Suppl 1): 4548.
  • 9
    Ursin G, Tseng C, Paganini-Hill A, et al. Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol. 2002; 20: 699706.
  • 10
    Lower EE, Blau R, Gazder P, Tummala R. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med. 1999; 7: 94954.
  • 11
    Recchia F, Sica G, De Filippis S, Rosselli M, Rea S. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer. A Phase II pilot study. Anticancer Drugs. 2002; 13: 417424.
  • 12
    Wintzer HO, Zipfel I, Schulte-Monting J, Hellerich U, von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer. 1991; 67: 421428.
  • 13
    Buzzoni R, Bonadonna G, Valagussa P, Zambetti M. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol. 1991; 9: 21342140.
  • 14
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 15
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205216.
  • 16
    Recchia F, Sica G, De Filippis S,et al. Beta interferon, retinoids and tamoxifen in the treatment of metastatic breast cancer. J Interferon Cytokine Res. 1995; 15: 605610.
  • 17
    Aebi S, Gelber S, Castiglione-Gertsch M, et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet. 2000; 355: 18691874.
  • 18
    Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896; 2: 104107.
  • 19
    Pagani O, O'Neill A, Castiglione M, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer. 1998; 34: 632640.
  • 20
    Bianco AR, Del Mastro L, Gallo C, et al. Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer. 1991; 63: 799803.
  • 21
    Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 1992; 339: 115, 71–85.
  • 22
    Love RR, Duc NB, Allred DC, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol. 2002; 20: 25592566.
  • 23
    Taylor CW, Green S, Dalton WS, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectony in patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol. 1998; 16: 994998.
  • 24
    Kaufmann M, Jonat W, Blamey R, et al. Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists' Group. Survival analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer. 2003; 39: 17111717.
  • 25
    Jakesz R, Hausmaninger H, Kubista E, et al., Austrian Breast and Colorectal Cancer Study Group Trial 5. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol. 2002; 20: 46214627.
  • 26
    Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer. 1990; 61: 861865.
  • 27
    Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998; 351: 14511467.
  • 28
    Osborne CK, Hobbs K, Clark GM. Effect of estrogen and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 1985; 45: 584590.
  • 29
    Soysal S, Soysal ME, Ozer S, Gul N, Gezgin T. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod. 2004; 19: 160167.
  • 30
    Sica G, Iacopino F, Robustelli della Cuna G, Marchetti P, Marini L. Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells. J Cancer Res Clin Oncol. 1994; 120: 605609.
  • 31
    Johnston JO, Wright CL, Holbert GW. Enzyme-activated inhibitors of steroideal hydroxylase. J Steroid Biochem Mol Biol. 1995; 52: 1734.
  • 32
    Gelber S, Coates AS, Goldhirsch A, et al. International Breast Cancer Study Group. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol. 2001; 19: 16711675.
  • 33
    Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offsprings after adjuvant chemotherapy in breast cancer patients. Cancer. 1990; 65: 847850.
  • 34
    Arriagada R, Le MG, Spielmann M, et al. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy. Ann Oncol. 2005; 16: 389396.